Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin
What is known and Objectives: Testing for cytochrome P450-2C9 (CYP2C9) and vitamin K epoxide reductase complex subunit 1 (VKORC1) variant alleles is recommended by the FDA for dosing of warfarin. However, dose prediction models derived from data obtained in one population may not be applicable to an...
| Published in: | Journal of Clinical Pharmacy and Therapeutics |
|---|---|
| Main Author: | |
| Format: | Article |
| Language: | English |
| Published: |
2012
|
| Online Access: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84857946108&doi=10.1111%2fj.1365-2710.2011.01262.x&partnerID=40&md5=c11f16571a9381ef4498e3894b730ba8 |